290 related articles for article (PubMed ID: 8389867)
1. Antinociceptive profile of biphalin, a dimeric enkephalin analog.
Horan PJ; Mattia A; Bilsky EJ; Weber S; Davis TP; Yamamura HI; Malatynska E; Appleyard SM; Slaninova J; Misicka A
J Pharmacol Exp Ther; 1993 Jun; 265(3):1446-54. PubMed ID: 8389867
[TBL] [Abstract][Full Text] [Related]
2. Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site.
Qi JA; Bowen WD; Mosberg HI; Rothman RB; Porreca F
J Pharmacol Exp Ther; 1990 Nov; 255(2):636-41. PubMed ID: 2173752
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
[TBL] [Abstract][Full Text] [Related]
5. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception.
Rady JJ; Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1991 Feb; 256(2):448-57. PubMed ID: 1847196
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
8. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
[TBL] [Abstract][Full Text] [Related]
9. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
10. Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors.
Vanderah TW; Wild KD; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Hruby VJ; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1993 Oct; 267(1):449-55. PubMed ID: 8229774
[TBL] [Abstract][Full Text] [Related]
11. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
12. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse.
Qi JN; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1990 Aug; 254(2):683-9. PubMed ID: 2166801
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
15. Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse.
Xu JY; Fujimoto JM; Tseng LF
J Pharmacol Exp Ther; 1992 Oct; 263(1):246-52. PubMed ID: 1328609
[TBL] [Abstract][Full Text] [Related]
16. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord.
Tseng LF; Narita M; Mizoguchi H; Kawai K; Mizusuna A; Kamei J; Suzuki T; Nagase H
J Pharmacol Exp Ther; 1997 Feb; 280(2):600-5. PubMed ID: 9023269
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
18. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1989 May; 249(2):462-9. PubMed ID: 2566676
[TBL] [Abstract][Full Text] [Related]
19. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
20. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
Bilsky EJ; Bernstein RN; Hruby VJ; Rothman RB; Lai J; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):491-501. PubMed ID: 8613959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]